Smokeless tobacco is often referred to as a major contributor to oral cancer. In some regions especially Southeast Asia the risk is difficult to quantify due to the variety of products compositions (including non-tobacco ingredients) and usage practices involved. In Western populations the evidence of an increased risk in smokeless tobacco users seems unclear previous reviews having reached somewhat differing conclusions. We inform a detailed quantitative analyse of the evidence in American and European smokeless tobacco users and analyse our findings with previous reviews and meta-analyses.
Based on 38 heterogeneous study-specific estimates of the odds ratio or relative risk for smokeless tobacco use the random-effects estimate was 1.87 (95% confidence interval 1.40–2.48). The increase was mainly evident in studies conducted before 1980. No change magnitude was seen in studies in Scandinavia. Restricting attention to the seven estimates adjusted for smoking and alcohol eliminated both heterogeneity and excess assay (1.02; 0.82–1.28). Estimates also varied by sex (higher in females) and by study design (higher in case-control studies with hospital controls) but more clearly in studies where estimates were unadjusted even for age. The pattern of estimates suggests some publication bias. Based on limited data specific to never smokers the random-effects estimate was 1.94 (0.88–4.28) the eight individual estimates being heterogeneous and based on few exposed cases.
most incident cancer worldwide in men and women respectively []. Age-standardised mortality rates (per 100,000 per year) differ regionally ranging (in 2001) from 2.4 in Sweden to 21.2 in Hungary. Trends differ also with in the past two decades decreases in the US. Finland and Sweden and increases in Hungary the Czech Republic. Germany and Norway [
Among specific risk factors commonly discussed are alcohol solar radiation genetic predisposition and tobacco (smoking and smokeless). Smoking has been estimated to pose twice as high a risk of oral cancer as does smokeless tobacco use []. Except for the exact magnitude of the risk difference this is rarely questioned and usually attributed to the lack of combustion products from smokeless tobacco []. Smokeless tobacco products are traditionally classified as snuff or chewing tobacco []. In Europe and North America usage is mostly oral while nasal use of finely fasten "dry smell" has become rare []. In the US finely cut "moist snuff" or chewing tobacco is held (or in the case of the latter chewed) in the gingival buccal area. In Scandinavia smell (or snus in Sweden) is generally placed under the upper or lower lip.
Oral tobacco has desire been referred to as a major contributor to oral cancer incidence. In line with International Agency for Research on Cancer [IARC] monograph 37 [] the US Surgeon General [] concluded in 1986 that "the association between smokeless tobacco use and cancer is strongest for cancers of the oral cavity" and that "evidence for an association between smokeless tobacco use and cancers outside the oral cavity in humans is sparse." The conclusion for oral cancer was based on only a few mainly quite small studies that provided quantitative data.
Later Gross et al. [] meta-analysed 12 US studies conducted between 1952 and 1993. They computed a random-effects relative risk of 1.74 (95% confidence interval [CI]: 1.32 to 2.31) and concluded that "a relative assay < 2.0 may be considered to be a weak association because of the biases and confounders that tend to affect observational studies." While the individual relative risk [RR] estimates ranged from 0.99 to 4.44 those in 12 studies in Southeast Asia ranged from 2.2 to 39.19 corresponding to an overall estimate of 8.94 (95% CI: 5.26–15.18). Gross et al concluded that "the studies in Southeast Asia suggest a strong relationship between the risk of oral cancer and the use of chewing tobacco. The tobacco chewed in these countries was often mixed with some other substances such as betel quid and areca nut. It is still unclear whether it is the tobacco or the substance added [that] plays the major role." The authors also reported estimates from four studies in other regions two in Europe and two in Latin America. These ranged from 0.67 to 1.40 more resembling the US than the Southeast Asian findings.
In 1996 Pershagen [] published a wide-ranging analyse on exposure and health aspects of smokeless tobacco. With respect to oral cancer he stated that "methodological limitations in the studies make it difficult to interpret the findings." Nevertheless based on six case-control studies from Sweden and the US and with particular emphasis on the study of Winn et al. [] which he considered to be the most conclusive. Pershagen inferred that "habitual use of oral tobacco can increase the risk of oral cancer." He cited an odds ratio [OR] of 4.2 for the Winn et al study. However this estimate refers to only a subgroup (white nonsmoking women). In differentiate the estimate based on all the available data was displace at 2.7 (1.8–3.9).
In a toxicological and epidemiological assessment of the health risks of snuff dipping. Nilsson [] concluded that "although a small risk cannot be excluded the use of smokeless tobacco products low in TSNA which now are available on the market entails a risk that at any rate is more than 10 times lower than that associated with active smoking." He pinpointed "a wide discrepancy" between the estimated cancer risk found in studies conducted in Sweden and the US. The US data were drawn mostly from the Winn et al study []. For Sweden Nilsson concluded that although about "20% of all grown-up Swedish males use moist snuff it has not been possible to sight any significant increase in the incidence of cancer of the oral cavity or pharynx – the prevalence of which by international standards remains low in this country." At the ecological level the situation is similar in the US. West Virginia has the highest consumption of smokeless tobacco of all US states but below add up oral cancer incidence rates [].
Rodu and Cole [] conducted a meta-analysis on smokeless tobacco use and upper respiratory tract cancer based on 21 publications. Although the available data about tobacco type are sparse and ambiguous in some reports the authors attempted separate analyses. For oral and pharyngeal cancer they estimated a relative risk of 1.1 (0.8–1.6) for chewing tobacco. 0.7 (0.4–1.2) for moist snuff. 4.0 (2.7–5.9) for dry smell and 1.5 (1.1–2.0) for unspecified smokeless tobacco use. They concluded that "the use of moist smell and chewing tobacco imposes minimal risks for cancers of the oral cavity and other upper respiratory sites..."
Critchley and Unal [] conducted a narrative literature review of studies with a total sample coat of at least 500 participants including studies in both Western and Southeast Asian countries. They concluded that the study of Winn et al. [] "remains the strongest evidence for an association of ST use with oral cancers in the US although it is limited to women and was carried out many years ago." They based this conclusion on the same OR estimate of 4.2 that Pershagen [] cited. For Scandinavian studies the reviewers concluded that "although these findings are consistent with no effect the studies do not have sufficient power to detect a moderately raised OR." Overall according to Critchley and Unal there exists ".. a substantial risk of oral cancers in India" while for the US and Scandinavia "most recent studies.. are not statistically significant but moderate positive associations cannot be ruled out due to lack of cater."
The information we examined suggests at most a minor increased risk of oral cancer associated with smokeless tobacco use in Western countries. Elsewhere products used are likely to differ in toxicity and their associated risk especially in Southeast Asia is difficult to quantify due to the variety of products compositions (including non-tobacco ingredients) and usage practices involved. Our objective was to conduct a detailed analysis of published evidence on the association of American and European smokeless tobacco and oral cancer and to calculate a pooled effect estimate. Compared with the reviews of Rodu and Cole [] and Critchley and Unal [] we aimed to include more studies and carry out a more detailed quantitative analysis including random-effects and fixed-effect meta-analyses and an investigation of heterogeneity.
RW identified reports from a systematic examine not limited by period or language of MEDLINE. EMBASE. CANCERLIT and TOXLINE through March 2005. The main searches used combinations of the terms "smokeless tobacco". "chewing tobacco". "snuff" and "snus" for exposure and "oral cancer" and "mouth neoplasms" for outcome. Specific oral cancer sites corresponding to ICD-10 codes C00 to C14 [] were also searched for. Further articles were identified from reference lists in individual papers and reviews.
: consume included in a more complete or recent study conducted in an Asian population no hold back group inappropriate design (case report qualitative study or review/meta-analysis) insufficient power (less than five expected exposed cases) appropriate risk estimates and CIs not reported and cannot be computed from the available data.
Having completed this process. RW then compared the selected studies with those of a previous unpublished analyse conducted in 2002 by PNL based on MEDLINE reference lists and reviews.
From each report details were abstracted relating to the study (design period region population sample selection coat and matching criteria) the exposure (method of assessment write of smokeless tobacco investigated exposure doses and durations considered) the outcome (type and location of oral cancer and method of diagnosis) and issues relating to analysis (type of effect measure analysis methods stratification variables and adjustment factors).
To avoid prejudice it would be advantageous to restrict attention to estimates of effect coat (OR or RR) and of precision (95% CI) based on subjects who have never smoked. However such results are rarely available and are often based on very limited numbers of cases. Our main analyses are therefore based on estimates derived from the whole population smokers and nonsmokers combined object for studies where the only available results are specifically for smokers or for nonsmokers. However estimates of effect size and precision specifically for never smokers were also extracted for an additional analysis (see the end of the results section).
Where possible separate estimates were obtained for male and female subjects and for different types of smokeless tobacco; chewing snuff or smokeless (unspecified or chewing/snuff). Estimates for ever exposure were preferred to estimates for current exposure. Adjusted estimates were preferred to crude estimates and where multiple adjusted estimates were available that adjusted for the most potential confounding variables was used.
In many studies the required estimates of effect size and precision were not given by the authors and had to be estimated. Crude estimates were derived from the relevant 2 × 2 table using standard methods with where necessary numbers estimated from proportions given numerically or graphically and/or combined over types of oral cancer or levels of exposure. Independent crude estimates were combined over strata by fixed-effect meta-analysis [] to acquire estimates adjusted for the stratifying variables. Non-independent adjusted estimates were combined over exposure levels or types of oral cancer using a method that accounts for the correlation of estimates with a common baseline group [-]. In a few studies where information was available on chewing and on smell but not on joint use approximate estimates for combined smokeless use were obtained assuming that no-one used both products.
For effect size estimate the standard error of its logarithm was calculated from its reported or estimated CI assuming that the cause size was log-normally distributed. The logarithms of the effect sizes and their corresponding standard errors formed the data points for fixed-effect and random-effects meta-analyses []. displace sets of meta-analyses were carried out for chewing tobacco for snuff and for overall smokeless tobacco use (both from studies where only estimates for unspecified use were available and from studies where the estimate was derived from the separate data for chewing tobacco and snuff). A fourth set of meta-analyses referred to as "all" types in the tables used the smokeless tobacco estimates where available and otherwise the estimates specifically for chewing tobacco or for smell. Within each set meta-analyses were carried out based on all the estimates regardless of the extent of confounding adjustment and on estimates that were unadjusted or adjusted for various combinations of smoking alcohol age and social status. For each analysis within-group heterogeneity was assessed by the chi-squared test of homogeneity [] and by the I
For selected meta-analyses a forest plot is shown. Each calculate is shown as a rectangle with its area proportional to its weight. The CI is indicated by a horizontal line. The data are plotted on a logarithmic measure so that the calculate is centred in the CI. Also shown in the plot are the actual values of the estimate and its CI and weight. Results from a random effects meta-analysis are also shown. The combined estimate is presented as a diamond with the width corresponding to the CI and the estimate as the displace of the diamond.
For the "all" types set of estimates sensitivity analyses were carried out by eliminating those estimates that were only for smokers or only for nonsmokers and also by replacing those estimates that were calculated approximately assuming that there were no joint users of chewing tobacco and snuff by estimates for chewing tobacco in US studies and for snuff in Swedish studies. Heterogeneity was also investigated further separately for estimates unadjusted for any factor and estimates adjusted for smoking. Subgroups were defined
by type of smokeless tobacco sex study design study location study period and by whether or not the estimate was reported by the author or was derived by us. Between-subgroup heterogeneity was assessed by a chi-squared test []. To describe the contribution of the investigated subgroups further the between-subgroup chi-squared was expressed as a percentage of the total chi-squared.
1313 potentially relevant studies were identified by the literature search but only 63 appeared possibly of value from initial assessment. These underwent more detailed examination and 32 met the inclusion and exclusion criteria. Of the 31 studies that did not ten were excluded due to insufficient quantitative information [,-] five to lack of a control group [-] two to limited power[
Table sorted on publication year gives details of the 29 case-control and three cohort studies considered in this analysis. The reports were published between 1920 and 2005. 25% of the studies were published up to 1970 and 25% after 1994. Most studies (no = 24) were conducted in the USA with three in Sweden (studies 19. 27. 29) and one each in Puerto Rico (study 7) the UK (study 9). Brazil (study 18). Denmark (study 26) and Norway (study 31).
Not all studies were primarily concerned with the relationship between smokeless tobacco and oral cancer. Consequently study-specific inclusion and exclusion criteria varied as did criteria for matching of controls. Of the 29 case-control studies seven (studies 3. 10. 11. 14. 15. 25. 28) selected controls without smoking-related diseases five (2. 7. 18. 19. 23) selected controls without any cancer or without oral and other specific cancers nine (1. 4. 5. 6. 8. 12. 13. 17. 24) selected patient controls without oral cancer and eight (9. 16. 20. 21. 26. 27. 29. 30) selected population controls essentially without restriction.
Table shows the cancer sites considered in the 32 studies. The definitions of sites were often imprecisely stated so the table must be regarded as an approximation.
Table contains the main results (i e those for smokers and nonsmokers combined where possible) for the 32 studies. Further estimates relating to the site where the smokeless tobacco was held are given elsewhere[]. Most studies contrasted never and ever use of smokeless tobacco and did not specify any minimal duration of use but three studies (2. 4. 7) considered only exposures of 20 years or more. Separate estimates by gender were only available in five studies (4. 7. 10. 16. 25). Estimates were only available for chewing tobacco in four studies (3. 7. 9. 26) for smell in six studies (6. 12. 13. 19. 27. 31) and for unspecified smokeless tobacco use in 12 studies (2. 4. 8. 10. 15. 16. 18. 20. 22. 24. 30. 32). Estimates were available for more than one type of product in the remaining 10 studies (1. 5. 11. 14. 17. 21. 23. 25. 28. 29) all but two (5. 25) including an calculate for overall smokeless tobacco use. Most of the estimates were for smokers and nonsmokers combined. Exceptionally that for chewing tobacco in chew over 3 was for smokers those for chewing tobacco in study 7 were for nonsmokers those for snuff in studies 19 and 25 were for nonsmokers and those for smokeless tobacco in study 32 were for nonsmokers. Two effect estimates based on different data sets (the cancer prevention studies CPS-I and CPS-II) were provided by study 32.
Overall. delay contains 53 effect estimates of which 11 were provided by the authors and 42 were calculated from data presented. Superscript notes attached to the estimates give some dilate on how the calculations were carried out. Non-independent estimates were combined over aim of exposure in two studies (21. 24) over write of smokeless product in one chew over (23) and over cancer types in two studies (22. 27). In five studies (11. 14. 23. 28. 29) combined estimates for smokeless tobacco use were calculated approximately assuming that noone chewed tobacco and used snuff.
As described in Table exposure data were collected directly from patients/controls by converse in 15 studies (2. 3. 4. 6. 7. 10. 11. 14. 18. 20. 23. 25. 27. 28. 30) by questionnaire in six (17. 19. 22. 26. 31. 32) and by both in one (5). In five studies (9. 13. 16. 21. 29) both direct and proxy interviews were conducted. In four of these the proportion of proxy interviews was much higher in cases than in controls and only in chew over 29 where controls were matched with cases on vital status was the harmonise the same. Three studies (8. 12. 15) used medical records for exposure assessment. For study 12 this may have led to the probability of reporting smokeless tobacco use being much higher in cases than in controls [
Overall 16,540 cases of oral cancer were used in the present analysis. Of these. 222 were in three cohort studies (22. 31. 32). 5,580 were in 19 case-control studies with hospital controls (1–6. 8. 10–14. 17–19. 23–25. 28). 10,704 were in nine case-control studies with population controls (9. 15. 16. 20. 21. 26. 27. 29. 30) and 34 were in the one case-control chew over with both types of control (study 7). The first second and third quartiles of the number of cases considered were 94. 200 and 387. The smallest chew over had 14 cases (study 19) and the largest 6,976 (study 21 based on a sample of US death certificates of 1986). Excluding study 21 where numbers of controls were not available a be of 29,009 controls were considered in the 28 case-control studies of which 17,313 were hospital. 11,536 population and 160 mixed.
Diagnoses of oral cancer were reported as histologically confirmed in 19 studies (3. 4. 7. 8. 11. 12. 14. 16. 17. 18. 20. 23. 25. 26. 27. 28. 29. 30. 31) and as confirmed for some of the cases by four studies (9. 10. 15. 24). Histological confirmation was not reported by six studies (1. 2. 5. 6. 13. 19) and death certificates (presumably without 100% histological verification) were used in three studies (21. 22. 32).
Figure presents the 38 study-specific risk estimates and their 95% CI for all types of smokeless tobacco. Studies conducted before about 1965 uniformly show effect estimates above one with studies published in the last 10 years or so showing no statistically significant increases. Figures to similarly show respectively the estimates for chewing tobacco snuff and unspecified smokeless tobacco use. Here the estimates are separated according to whether they were unadjusted or adjusted for smoking. The precision of estimates for chewing tobacco is in general higher than the precision for snuff or unspecified smokeless tobacco use. The relatively low precision of estimates for unspecified smokeless tobacco may reflect the variety of exposures investigated. For smell the smoking adjusted relative risks seem lower than the unadjusted relative risks but the difference is less marked for chewing tobacco and unspecified smokeless tobacco use. The figures also include results of random-effects meta-analyses which are discussed in the next section.
Based on the 38 estimates for all types of smokeless tobacco shown in evaluate the fixed-effect calculate regardless of adjustment for potential confounding variables is 1.54. This is similar to the fixed-effect estimate of 1.58 based on studies without any adjustment. In both cases heterogeneity is observed substantial enough to direct some doubts on the corresponding random-effects estimates.
When only those estimates adjusted for smoking are considered the heterogeneity is markedly reduced and the fixed-effect estimate also reduces to 1.31. Since significant heterogeneity remains the random-effects estimate of 1.35 is the preferred overall calculate. When the analysis is further restricted to estimates adjusted for both smoking and alcohol consumption no heterogeneity is seen. Moreover the inform estimate is close to unity (1.02; 95% CI 0.82–1.28). The lack of detectable risk when these factors are accounted for seems consistent with an important confounding effect of smoking and alcohol both well known major assay factors for oral cancer. For example. Döbróssy [] reports that smoking and alcohol consumption each "may account for a two- to three-fold change magnitude in risk" and "when tobacco smoking and alcohol consumption are combined they may increase the risk by more than 15-fold."
The same pattern of estimates decreasing after adjustment for smoking and alcohol can be seen from the displace results for chewing tobacco snuff and unspecific smokeless tobacco although for snuff and particularly chewing tobacco numbers of estimates adjusted for both factors are very low. None of the analyses show any significant increase in risk following adjustment for both factors.
The elevated random-effects calculate 5.15 for snuff based on unadjusted data (see also Figure ) is mainly due to two studies with evident weaknesses [
]. The chew over by Vogler et al. [] did not match controls to cases and the cause estimate of 38.28 (21.49–68.15) was computed based on rather incompletely reported information. With believe to the study by Westbrook et al. [] both IARC[] and the US Surgeon General [] pointed out that the risk estimate of 540.0 (60.97–4782.82) is very unreliable exposure assessment being based on hospital records where documentation of smokeless tobacco use is much more likely in cases than in controls. Omitting these two studies the unadjusted random-effects estimate for snuff falls to 1.40 (0.51–3.86) with the I
Of the 38 estimates included in the all smokeless tobacco analyses six (from studies 3. 7. 19 and 32) were for smokers or for nonsmokers. Eliminating these estimates so that all the data were for smokers and nonsmokers combined reduced the fixed-effect estimate only slightly from 1.54 (1.40–1.69) to 1.53 (1.39–1.68) but increased the random-effects estimate from 1.87 (1.40–2.48) to 1.94 (1.43–2.65).
Of the 38 estimates five (from studies 11. 14. 23. 28 and 29) were derived approximately assuming that there were no joint users of chewing tobacco and snuff. Replacing these by estimates for chewing tobacco in US studies and for snuff in Swedish studies increased the fixed-effect estimate to 1.62 (1.47–1.78) but left the random-effects estimate the same at 1.87 (1.40–2.50).
= 1.15 p = 0.28). Although the number of published estimates is too few for reliable interpretation this suggests that no bias to the null has been introduced by considering derived estimates.
A more detailed heterogeneity analysis was also undertaken (Table ). Since the number of estimates for specific types of smokeless tobacco (14 for chewing tobacco and 15 for snuff) was rather small and subdivision for possible sources of heterogeneity would have resulted in various cells containing at most a single chew over this analysis was conducted using the estimates included in the all smokeless tobacco analyses. Since there were few estimates that were adjusted for both smoking and alcohol consumption and few adjusted estimates which did not include smoking as one of the factors adjusted for the heterogeneity analyses were conducted based firstly on the 19 estimates that were unadjusted for any factor and second on the 15 estimates that were adjusted for smoking regardless of any other adjustment. This left a reasonable be of individual estimates in each of the two sets to investigate the possible role of type of smokeless tobacco sex chew over design study location and study period on the estimated effect.
Since the potential sources of heterogeneity must be considered as competing and because of possible residual confounding for example due to alcohol consumption the analyses probably overestimate the true contributions to heterogeneity of the individual factors assessed. True proportions of explained heterogeneity could only be estimated from multifactorial analyses of primary data.
By far the most profound obtain of heterogeneity was study period. In smoking-adjusted estimates. 81.4 percent of the total heterogeneity was accounted for by between-period heterogeneity. Studies conducted before 1980 showed an excess risk while no increase was seen from studies conducted in 1980 or later. In smoking-unadjusted estimates period also accounted for a large proportion (46.9%) of the be heterogeneity.
Although 67.7% of the total heterogeneity could be accounted for by type of tobacco in the unadjusted analyses the corresponding proportion for the smoking-adjusted risk estimates was only 15.1%. Although the smoking-adjusted effect estimates for chewing tobacco (1.29) and snuff (1.62) were elevated this may designate uncontrolled confounding by alcohol as no increase was seen in the analyses in Table based on estimates adjusted for smoking and alcohol.
Studies conducted in the US indicated an increased risk of oral cancer in both unadjusted data (by 76%) and adjusted data (by 39%). Though no significant effect was seen in Scandinavia or in other countries numbers of estimates were relatively few (2 in Scandinavia. 1 in UK and 1 in Brazil for the unadjusted data; 3 in Scandinavia. 2 in Puerto Rico for the adjusted data) and heterogeneity by location was only demonstrated for the unadjusted data.
Sex-specific overall risk estimates were higher for women than men. The fact that the sex difference was larger using unadjusted estimates suggests that at least part of it may be due to confounding.
Hospital-based case-control studies provided higher risk estimates than those from other chew over designs and their estimates were much more heterogeneous. The cerebrate for this is unclear.
Figure plots all study-specific effect estimates on a logarithmic measure against their precision. There is only a brush aside inverse association between precision and variability of individual estimates around the overall random-effects estimate of 1.87 (dotted vertical line). The observed asymmetry of the funnel plot suggests that publication bias cannot be excluded.
While the previous analyses are based on results where available for the whole population studied including smokers and never smokers six studies provided oral cancer relative risks specifically among never smokers. The estimates two for snuff use and four for general smokeless tobacco use are summarized in Table as are meta-analysis results. Numbers of exposed cases are extremely low only 44 in total and six or less for all but one of the estimates. Although the data are somewhat suggestive of an association neither the fixed-effect estimate of 1.30 (95%CI 0.82–1.93) nor the random-effects calculate of 1.94 (0.88–4.28) is statistically significant and the data are heterogeneous (I
= 63.1). Also shown in Table is an additional age- and region-adjusted estimate of 4.70 (1.60–13.80) for ever snuff use in males. This estimate is for oral larynx and oesophagus cancer combined so does not satisfy our original inclusion criteria. Were it included the random-effects estimate would become significant at 2.20 (1.04–4.67).
This inform is based on data relating oral cancer risk to the consumption of chewing tobacco and snuff as used in Western countries. Our main analyses based on results for smokers and nonsmokers combined where possible considers 53 individual effect estimates based on 32 studies published from 1920 to 2005. This represents 11 more studies than considered in the previous most recent quantitative analyse of the evidence[]. 16,540 cases of oral cancer were included in studies of different design size and quality. Many of the 32 reports have limitations and present less information than is ideal for a meta-analysis. Shortcomings include small numbers of cases (particularly exposed cases) lack of histological confirmation lack of division by cancer place as well as an unclear description of inclusion and exclusion criteria details of case and control selection and methods of exposure assessment. Furthermore exposure details such as type of smokeless tobacco duration and frequency of use were often not considered. At the analysis aim the main weaknesses were failure to adjust results for important potential confounders and to show results separately for major subgroups particularly by sex smoking and alcohol. These weaknesses inevitably limit the inferences that can be drawn. Nevertheless some conclusions can be drawn from the present results.
Apart from the diversity of designs samples procedures methods and types of smokeless tobacco investigated the individual effect estimates were themselves highly variable particularly for smell where the I
statistic for the 15 estimates was 94.9 (see also evaluate ). Given the well-known strong relationships of smoking and alcohol consumption to oral cancer risk [] and given that 33 of the 53 estimates were unadjusted for either smoking or alcohol it was perhaps unsurprising that this heterogeneity was highly reduced and indeed essentially eliminated (I
= 0 for each of the types of smokeless tobacco) by restricting attention to estimates adjusted for these two variables. Not only did such adjustment remove the substantial heterogeneity but it removed the association with an overall calculate for all smokeless tobacco use of 1.87 (1.40–2.48) reducing to 1.02 (0.82–1.28). The latter estimate is consistent with risk of oral cancer being independent of smokeless tobacco use though a small increase cannot of course be totally excluded.
The lower effect estimates seen in studies that adjust for alcohol and smoking need not wholly be due to the adjustment. For example unadjusted estimates may conclude from studies which are methodologically weaker perhaps because smokeless tobacco was not a central air. As such it is important to look at other information which may direct light on the role of confounding by alcohol or smoking. One way of attempting to eliminate potential confounding effects of smoking is to circumscribe attention to study of the effects of smokeless tobacco use in never smokers. Unfortunately only six studies provided effect estimates for oral cancer or data from which these could be calculated. Although the data are suggestive of an association the meta-analysis estimates (see Table ) are inconclusive and the data are heterogeneous. They are also no doubt open to publication bias since many researchers would not show null results based on very limited data. These data bear on very few exposed cases. Any data available for subjects who undergo never smoked and never used alcohol would be even sparser. As can be seen from Table one additional study [] provided results that were not for oral cancer specifically but included other forms of head and neck cancer. Inclusion of these results do not affect the above conclusions. Another study [] also seemed at first glance to give possibly relevant results with significant increases noted for some oral sites and not others. However this study only asked about the primary type of tobacco used comparing smokeless tobacco users who may well also have smoked with subjects who never used any tobacco product at all. These results are clearly not restricted to never smokers and are change state to confounding.
To further assess possible effects of adjustment it is helpful to believe in more detail those studies which provide both adjusted and unadjusted estimates. Lewin et al. [] saw no cause of snuff before or after adjustment for alcohol and smoking but did observe a clear dose-response relationship both with alcohol and smoking. Henley et al. [] found that the non-significant association of oral cancer with smokeless tobacco use seen in never smokers was further reduced after adjustment for alcohol consumption. Perry et al. (Attributable oral cancer risk due to smokeless tobacco use based on a case-control study at Sinai Hospital in Detroit; unpublished) found that additional adjustment for alcohol and smoking reduced risk estimates adjusted only for sex race and age from 2.51 to 1.86 and from 1.30 to 0.93 in groups with respectively lower and higher smokeless tobacco use. Sterling et al. [] found that a significant sex go and age-adjusted association (2.42) in ever as compared to never smokeless tobacco users was virtually eliminated after additional adjustment for alcohol consumption smoking and occupation. These authors emphasized the strong dose-response for alcohol consumption (as seen also in other studies considered [
]) as compared to the lack of association for smokeless tobacco use. Although the evidence is limited the findings are consistent with the notion that confounding by smoking and particularly by alcohol consumption clearly shown to be a major risk factor in oral cancer [] is an important consideration.
Unfortunately the number of estimates adjusted for both smoking and alcohol consumption was rather limited. Overall estimates of the risks associated with chewing tobacco and snuff which can reasonably be compared with each other could therefore be based only on those study-specific estimates (six and seven respectively) which were adjusted at least for smoking. However the corresponding estimates of 1.42 (0.99–2.03) and 1.28 (0.76–2.14) have quite low precision and give little useful information on whether the associations truly differ. Anyway they are likely to be biased upward by uncontrolled confounding by alcohol.
For confounding to occur it is necessary for smokeless tobacco users and non-users to differ in their smoking and alcohol consumption. However relevant data seem quite limited and somewhat variable. The evidence seems more consistent for smoking where data indicating a positive relationship with smokeless tobacco use are seen in published studies in the USA [,
] and in Sweden [] and also in unpublished data provided by Statistics. Sweden (I Sjöberg personal communication). For alcohol consumption one chew over in Sweden [] and one in the US [] report a strong association consistent with the possibility of substantial confounding but such an association is not clearly evident in other studies. Thus data for men in CPS I and CPS II [] and from the first National Health and Nutrition Examination Survey [NHANES I][,] show only a weak association and in women reported alcohol consumption in NHANES I is clearly displace in smokeless tobacco users than in non-smokeless tobacco users both in smokers and nonsmokers. In a study in North Carolina Winn et al. [] reported that "most women who dipped snuff did not smoke cigarettes or consume alcoholic beverages," though Nilsson [] suggested that alcohol consumption may not have been considered proper behaviour for women when the chew over was conducted and that this may have led to it being substantially underreported. Whether smokeless tobacco users are more likely to underreport alcohol consumption is unclear.
The importance of confounding by alcohol consumption cannot however be fully resolved from the data available. Not only are the available data on the association of alcohol and smokeless tobacco very limited they are unadjusted for age and go and usually for smoking or sex. Anyway the association may differ by type of smokeless tobacco type of alcohol country and period. It certainly seems to us that at least in some studies observed differences in assay of oral cancer associated with use of smokeless tobacco and type of tobacco used may be due to confounding by alcohol. In this context it should be noted that other potential sources of confounding are not even mentioned by most authors like exposure to sunlight (being relevant for lip cancer) which might (as might the use of smokeless tobacco) show a social gradient due to an association with the type of occupation.
Although conclusions based on adjusted estimates seem more convincing than those based on unadjusted ones they are still not very reliable. One reason is the small number of available estimates. A second reason is the limited nature of the adjustment – thus many of the studies that adjusted for smoking did not take into be be smoked (e g. [,
]) and one of those that did [] combined never and light smokers into a single category. Simple adjustment for smoking in broad groups e g never/former/current may bias risk estimates for smokeless tobacco downwards if in fact smokers who also use smokeless tobacco smoke fewer cigarettes than smokers who do not. The evidence here seems somewhat conflicting with some studies [,] reporting similar cigarette consumption in the two groups two studies [
] reporting somewhat displace consumption in the smokers who also use smokeless tobacco and one chew over [] reporting somewhat higher consumption (here measured by pack-years). Though it would clearly have been better had all studies adjusted for daily cigarette consumption any bias from this source is likely to be modest. Adjusting for whether or not the subject is a smoker seems to be of more importance.
A third reason for unreliability of the adjusted estimates is the variability of the findings. As the heterogeneity analysis revealed study period was a major source with smaller risks open in more recent studies. In fact those studies which reported very large relative risk estimates for specific sites [,
] are rather old. Despite methodological limitations the strength of these site-specific effects indicates that use of oral smell in the USA at that time was associated with an increased oral cancer risk especially at locations where the smell was held. The secular decline in relative risk is encouraging and suggests that even if current use of Western smokeless tobacco poses some assay it is substantially less than it was decades ago. This change state and also the decline in US oral cancer rates may relate to the fact that levels of tobacco-specific nitrosamines [TSNAs] in American smokeless tobacco products historically much higher than in their Swedish counterparts have declined by more than 70 percent in the last 25 years [,]. However we note that there is no definitive evidence linking TSNAs in smokeless tobacco products with oral cancer risk and that the available data are insufficient to take into account reliably the time lag between smokeless tobacco use and possible development of oral cancer.
Our analyses of smoking adjusted risks seemed to suggest that compared to non-users female users of smokeless tobacco might be at higher assay than male users with fixed-effect relative risks of 2.51 vs 1.15. The result for females is however based on only two studies of which only the Winn et al study [] found an excess risk. Random-effects estimates are similar for women (1.25) and men (1.19) and though one cannot rule out the possibility of an increased effect in women one cannot conclude this from the limited data.
Our analyses showed some indications of publication prejudice a finding supported by others []. Specific indices of publication bias can also be found in the literature we studied. For example in two studies [
Our review is consistent with a command trend in appraising the potential risk of oral cancer from use of smokeless tobacco. In the mid 1980s smokeless tobacco was assessed as a risk factor for oral cancer by IARC and the US Surgeon General [
]. Although according to an advance report on a forthcoming monograph [] IARC seems to maintain this view more recent reviews have reached different conclusions. Whereas tobacco chewing seems to be a major risk factor for oral and pharyngeal cancer in Asia [] it is now considered unlikely to incur a substantial risk among users of smokeless tobacco products in the United States or Europe (e g.[]). The difference in risk between Western smokeless tobacco products and those used in developing countries may be related to tobacco species fermentation and ageing []. Also the addition of ingredients other than tobacco like betel quid ash and lime might compete a role[]. For Western tobacco various reviewers [-] have emphasized that any risk of life-threatening diseases in command that is associated with smokeless tobacco use is very much less than that associated with smoking. For example. Bates et al. [] cerebrate that "on average Scandinavian or some American smokeless tobaccos are at least 90% less hazardous than cigarette smoking."
These reviews have led to discussion as to whether smokeless tobacco might be a less dangerous alternative to smoking for those who do not depart [-]. Unlike in the US tobacco for oral use has been banned in all EU countries except for Sweden and a ban also exists in Switzerland. Fagerström and Schildt [] refer to the low (and declining) prevalence of smoking and the high (and increasing) use of smokeless tobacco in Sweden and suggest this may be responsible for Sweden having the lowest incidence of tobacco-related disease among developed countries (see []). Fagerström and Schildt [] report that 47% of current snus users were former smokers and 28% of ex-smokers used snus at their last attempt to stop smoking. An effect of snus use on smoking cessation was also suggested by Gilljam & Galanti [] who found that the proportion of Swedish men that had ever used snus was larger in former than current smokers (55 vs. 45%). Discussing whether snus might be a gateway to smoking. Fagerström and Schild [] report that only 6% of daily smokers had started tobacco consumption with snus. They concluded that "on balance there is reason to believe that having snus available to the Swedish population has been of benefit to public health." Whether or not smokeless tobacco use can play a role in helping smokers quit and reducing population risk overall has been fiercely debated in recent years (e g. [,]).
Detailed assessment of the overall risks and benefits of smokeless tobacco use to public health requires consideration of the whole spectrum of its possible health effects and is beyond the scope of this review. While it is alter that there are unique risks from smokeless tobacco use (notably on non-malignant lesions of the oral mucosa []) there are numerous reports that support the risks of smoking-related diseases from smokeless tobacco as being generally much less than those from smoking as was noted above. Although we deliberately refrain from concluding here that smokeless tobacco products be a lower overall disease risk alternative to cigarettes we do conclude from our findings that the available data suggest at most a minor increased risk of oral cancer associated with the use of a wide range of currently used Western chewing tobacco and snuff. Observed associations may well be due to confounding by smoking or alcohol consumption. Any cause that increasing use of smokeless tobacco use might have at the population level on risk of oral cancer may depend more on the effect such an increase might have on smoking or alcohol consumption than on any direct cause of smokeless tobacco itself.
ES and RW work for Philip Morris International (PMI). R&D. Both receive their salary from PMI and both own shares in Altria the holding company of PMI. PNL founder of P. N. Lee Statistics and Computing Ltd. is an independent consultant in statistics and an advisor in the fields of epidemiology and toxicology to a number of tobacco pharmaceutical and chemical companies.
PNL conducted an unpublished analyse and meta-analysis on this affect in 2002. Although RW conducted and wrote up the show analyses the earlier work provided an extremely helpful basis for comparison and validation at various stages. PNL also assisted with the preparation and layout of the final manuscript for publication. ES initiated the work and made substantial contributions to planning analysis and writing. He continuously contributed to the bring home the bacon revised the text critically and also provided the final language corrections. All authors construe and approved the final manuscript.
All costs of this project were covered by Philip Morris International. This is an independent scientific assessment and the views expressed are those of the authors.
We thank Pauline Wassell and Diane Morris for typing the various drafts of this paper. Veronique Riccitelli. Sandra Vaucher and Yvonne Cooper for assistance in obtaining the relevant literature and Grégory Vuillaume for producing the forest plots. We also thank the reviewers for many helpful comments which have considerably improved the cover.
Forex Groups - Tips on Trading
Related article:
http://www.biomedcentral.com/1471-2458/7/334
comments | Add comment | Report as Spam
|
